On Friday, Viridian Therapeutics Inc (NASDAQ: VRDN) opened higher 5.35% from the last session, before settling in for the closing price of $11.41. Price fluctuations for VRDN have ranged from $9.90 to $27.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -4.11%. Company’s average yearly earnings per share was noted -6.05% at the time writing. With a float of $73.28 million, this company’s outstanding shares have now reached $80.99 million.
Considering the fact that the conglomerate employs 143 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -1931.79%, operating margin of -99018.54%, and the pretax margin is -89387.09%.
Viridian Therapeutics Inc (VRDN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viridian Therapeutics Inc is 10.07%, while institutional ownership is 102.36%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.74% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Check out the current performance indicators for Viridian Therapeutics Inc (VRDN). In the past quarter, the stock posted a quick ratio of 15.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3264.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.77, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -3.96 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Compared to the last year’s volume of 1.04 million, its volume of 1.27 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 45.17%. Additionally, its Average True Range was 1.02.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 15.42%, which indicates a significant decrease from 38.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.59% in the past 14 days, which was higher than the 62.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.46, while its 200-day Moving Average is $18.03. Nevertheless, the first resistance level for the watch stands at $12.36 in the near term. At $12.71, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.33. If the price goes on to break the first support level at $11.39, it is likely to go to the next support level at $10.77. Should the price break the second support level, the third support level stands at $10.42.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are currently 81,485K shares outstanding in the company with a market cap of 979.39 million. Presently, the company’s annual sales total 300 K according to its annual income of -269,950 K. Last quarter, the company’s sales amounted to 70 K and its income totaled -79,730 K.
